NCAG1 inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of NCAG1, a protein that is thought to play a role in cellular growth, metabolism, or signaling pathways. While the exact biological functions of NCAG1 remain under investigation, proteins in this family are typically involved in critical regulatory mechanisms that control cellular processes such as transcription, protein-protein interactions, or metabolic pathways. By inhibiting NCAG1, researchers can explore its specific contributions to these processes, studying how its regulation affects cellular homeostasis, signal transduction, and other aspects of cellular function.
The mechanism of action for NCAG1 inhibitors generally involves binding to key functional domains of the protein, preventing it from interacting with its molecular partners or executing its biological role. Structurally, NCAG1 inhibitors may mimic natural substrates or ligands of the protein, competitively blocking its active site or binding regions essential for its activity. Alternatively, inhibitors may interact with allosteric sites on NCAG1, inducing conformational changes that render the protein inactive. Through the inhibition of NCAG1, researchers gain valuable insights into how this protein influences broader signaling or metabolic pathways and how its activity modulates cellular dynamics. These inhibitors are essential for elucidating the molecular mechanisms behind NCAG1's role in maintaining cellular balance, providing deeper understanding into the regulatory networks that depend on this protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
A polysulfonated naphthylurea that inhibits various growth factors and enzymes, potentially impacting glycosaminoglycan-related pathways. | ||||||
Fondaparinux | 104993-28-4 | sc-507424 | 10 mg | $297.00 | ||
A synthetic pentasaccharide that inhibits Factor Xa, potentially influencing dermatan sulfate-associated coagulation pathways. | ||||||
N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine-d3 | 808118-40-3 unlabeled | sc-488006 | 10 mg | $12000.00 | ||
A mixture of heparan sulfate, dermatan sulfate, and chondroitin sulfate, affecting anticoagulation pathways. | ||||||
Chondroitinase ABC from Proteus vulgaris | 9024-13-9 | sc-507341 | 2 U | $650.00 | ||
An enzyme that degrades chondroitin sulfate and dermatan sulfate, potentially altering their biological functions. | ||||||
Heparin | 9005-49-6 | sc-507344 | 25 mg | $119.00 | 1 | |
An anticoagulant that interacts with various glycosaminoglycans and may affect pathways related to dermatan sulfate. | ||||||
Warfarin | 81-81-2 | sc-205888 sc-205888A | 1 g 10 g | $73.00 $246.00 | 7 | |
An anticoagulant that inhibits vitamin K epoxide reductase, indirectly affecting glycosaminoglycan-related coagulation processes. | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $158.00 | 18 | |
A direct Factor Xa inhibitor, potentially influencing coagulation pathways related to dermatan sulfate. | ||||||
Apixaban | 503612-47-3 | sc-364406 sc-364406A | 10 mg 50 mg | $240.00 $634.00 | 2 | |
Another Factor Xa inhibitor, potentially affecting coagulation processes involving dermatan sulfate. | ||||||
Dabigatran | 211914-51-1 | sc-481166 | 5 mg | $205.00 | 1 | |
A direct thrombin inhibitor, possibly impacting coagulation pathways associated with dermatan sulfate. | ||||||